Clinical-stage life sciences company Revelation Biosciences Inc (NASDAQ:REVB) on Tuesday announced the initiation of its PRIME Phase 1b clinical study of Gemini in patients with Stage 3 and 4 Chronic Kidney Disease (CKD).

This study will evaluate escalating doses of intravenously administered Gemini in a multi-site, placebo-controlled trial. Top-line data, including safety and tolerability, are expected by mid-year.

Gemini is a proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) that reduces the damage associated with inflammation by reprogramming the innate immune system to respond to stress (trauma, infection, etc) in an attenuated manner.

Revelation is developing Gemini for multiple indications, including acute kidney injury, post-surgical infection, and chronic kidney disease.